Abstracts tagged "Cardiovascular disease"

Abstract Number: 1437 • 2014 ACR/ARHP Annual Meeting
Cholesterol Efflux Capacity of HDL and Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Patricia Yancey², Suguru Yamamoto², Annette M. Oeser¹, Tebeb Gebretsadik³, Ayumi Shintani¹, MacRae F. Linton¹, Sergio Fazio¹, Sean Davies¹, L Jackson Roberts II¹, Kasey C. Vickers¹, Paolo Raggi⁴, Valentina Kon¹ and C Michael Stein¹, ¹Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Biostatistics, Vanderbilt University, Nashville, TN, ⁴Emory University, Atlanta, GA
Background/Purpose: Cardiovascular (CV) risk is increased in patients with rheumatoid arthritis (RA), but not fully explained by traditional risk factors such as LDL and HDL…
Abstract Number: 1064 • 2014 ACR/ARHP Annual Meeting
Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control
Ulf Müller-Ladner¹, Stefan Kleinert², Klaus Krüger³, Bianca Wittig⁴ and Rolf Hecker⁴, ¹Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Abt. Rheumatologie und klinische Immunologie, Bad Nauheim, Germany, ²Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ³Praxiszentrum St. Bonifatius, München, Germany, ⁴Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany
Background/Purpose More than 50% of premature deaths in patients with rheumatoid arthritis (RA) are due to cardiovascular disease (CVD). Both the cumulative burden of inflammation…
Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 2936 • 2014 ACR/ARHP Annual Meeting
Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases, and How Does These Risks Compare to Those in Rheumatoid Arthritis?
Johan Askling¹, Lennart Jacobsson² and Jonas Eriksson¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²sahlrenska academy, gothenburg, Sweden
Background/Purpose Patients with RA are at increased risk of cardiovascular (CV) diseases, including acute coronary syndromes (ACS), deep venous thromboembolism (DVT) and pulmonary embolism (PE),…
Abstract Number: 2103 • 2014 ACR/ARHP Annual Meeting
Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting
E Alemao¹, S Joo², H Kawabata¹, S Banerjee¹, M Frits³, C Iannaccone³, N Shadick³ and M Weinblatt³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Guidelines in RA recommend that treatment should be aimed at reaching a target of remission or low disease activity (LDA) as soon as possible,…
Abstract Number: 1413 • 2014 ACR/ARHP Annual Meeting
The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis
Marion Couderc Sr.¹, Martin Soubrier², Bruno Pereira³, Aurelien Tiple⁴, Melanie Gilson⁵, Bruno Fautrel⁶, Sophie Pouplin⁷, Emmanuelle Dernis Labous⁸, Laure Gossec⁹, Cécile Gaujoux-Viala¹⁰ and Maxime Dougados¹¹, ¹Chu G.Montpied, Clermont Ferrand, France, ²Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Nephrology, CHU, Clermont-Ferrand, France, ⁵Rheumatology, CHu Grenoble, Grenoble, France, ⁶Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁷Rheumatology, Rouen University Hospital, Rouen, France, ⁸Rhumatologie, Ch Du Mans, Le Mans, France, ⁹Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ¹⁰EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ¹¹Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA). Methods: COMEDRA is a French nationwide cross-sectional multicentre study…
Abstract Number: 1063 • 2014 ACR/ARHP Annual Meeting
Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting
Kashif Jafri¹, Lynne Taylor², Nehal N. Mehta³, Melissa Nezamzadeh⁴, Joshua Baker⁵ and Alexis Ogdie⁶, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁶Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis has been associated with an increased risk of cardiovascular morbidity and mortality. It is unclear, however, whether this knowledge has translated into…
Abstract Number: 385 • 2014 ACR/ARHP Annual Meeting
Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial
EA Alemao¹, S Joo², S Banerjee¹, P Allison³, P Emery⁴, M Weinblatt⁵ and Katherine Liao⁶, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Leeds, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: We developed and validated a prognostic model for rapid radiographic progression (RRP) using X-ray data to identify RA patients (pts) at risk of structural…
Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
Abstract Number: 2098 • 2014 ACR/ARHP Annual Meeting
Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis
Alf Kastbom¹, Lisbeth Ärlestig² and Solbritt M. Rantapää-Dahlqvist³, ¹Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose Inflammasomes are intra-cellular protein complexes important for the production of pro-inflammatory cytokines such as interleukin-(IL-)1β and IL-18. Cardiovascular disease is over-represented in patients with…
Abstract Number: 1410 • 2014 ACR/ARHP Annual Meeting
Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies?
Kimberly P. Liang¹, Rohit Aggarwal², Juan (June) Feng³, Jason Lyons³, Heather Eng³, Stephen R. Wisniewski³, Melissa Saul⁴, Douglas P. Landsittel⁵, Douglas W. Chew¹, Aryan Aiyer⁶ and Larry W. Moreland⁷, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, ⁵Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ⁶Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite higher risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA), systematic cardiovascular (CV) prevention strategies are lacking. Recent guidelines for CV risk…
Abstract Number: 945 • 2014 ACR/ARHP Annual Meeting
Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy
Thomas Schau¹, Michael Gottwald², Christian Butter¹ and Michael Zaenker³, ¹Cardiology Dept., Immanuel Klinikum Bernau Heart Center Brandenburg, Bernau, Germany, ²Internal Med. Dept., Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany, ³Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany
Background/Purpose Risk of heart failure (HF) is increased in patients with RA, however there is great variance in reported prevalence rates due to different diagnostic…
Abstract Number: 355 • 2014 ACR/ARHP Annual Meeting
Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Atsuma Nishiwaki³, Hirotake Inomata¹, Noboru Kitamura¹, Hidetake Shiraiwa³, Takamasa Nozaki³, Natsumi Ikumi⁴ and Masami Takei⁵, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) experience an excess risk of congestive heart failure (CHF), but effects of disease-modifying anti-rheumatic drugs (DMARDs) on cardiac structure…
Abstract Number: 2889 • 2014 ACR/ARHP Annual Meeting
The Association Between Changes in Inflammation and High Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis
K P Liao¹, Martin Playford², Michelle A. Frits³, Christine K. Iannaccone⁴, Jonathan S. Coblyn¹, Michael E. Weinblatt⁵, Nancy A. Shadick⁶ and Nehal N. Mehta⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²National Heart, Blood, and Lung Institute, Bethesda, MD, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/Harvard University, Cambridge, MA, ⁷Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures the functional ability of HDL to remove cholesterol from atherosclerotic plaque. Low HDL efflux capacity is…
Abstract Number: 2084 • 2014 ACR/ARHP Annual Meeting
Are Genetic Markers Associated with Myocardial Infarction in Patients with Early Rheumatoid Arthritis?
Lisbeth Ärlestig¹, Petros Zamout², Lena Innala³, Eva Freyhult⁴, Solveig Wållberg Jonsson² and Solbritt Rantapää-Dahlqvist², ¹Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umea, Sweden, ²Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ⁴Bioinformatics Infrastructure for Life Sciences, Uppsala, Sweden
Background/Purpose Cardiovascular disease (CVD) are increased in patients with rheumatoid arthritis (RA). Traditional as well as disease related risk factors seem to contribute to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].